Accuray Incorporated Announces Major 1-for-40 Reverse Stock Split for Common Shares

Accuray Announces 1-for-40 Reverse Stock Split

Accuray Incorporated, a prominent player in the field of radiation therapy, has officially announced a significant financial restructuring initiative: a 1-for-40 reverse stock split of its common stock. This decision, made by the Board of Directors, comes as a strategic move to enhance the trading price of its shares and ensure compliance with the minimum bid price requirements set by The Nasdaq Capital Market, commonly referred to as Nasdaq.

This reverse stock split is set to take effect at 12:02 a.m. Eastern Time on November 9, 2026. Following this split, shares of common stock will begin trading adjusted for the split under the existing trading symbol 'ARAY' when the Nasdaq market opens on the same day. Notably, the split will significantly reduce the number of outstanding shares from approximately 120.2 million to an estimated 3 million shares, pending adjustments for any fractional shares.

Additionally, the total number of authorized shares will also see a proportional reduction in line with the reverse split ratio. This will decrease the authorized shares from 400,000,000 to a more manageable 10,000,000 shares. However, the company’s preferred stock will remain unchanged.

Impact on Stockholders

Despite these adjustments, it is vital for current shareholders to understand that their percentage of ownership will remain unaffected, barring adjustments for fractional shares. For those entitled to fractional shares, the company will provide cash in lieu of a fractional share rather than issuing new shares. The equity awards and any other securities linked to the stock will also be adjusted appropriately to reflect this stem.

The move is indicative of Accuray's commitment not just to stability but also to growth. The restructuring is part of a broader strategy aimed at revitalizing share prices amid a dynamic economic landscape. Stakeholders and investors looking for signals of recovery in Accuray's market presence can take this as an optimistic development. With plans to enhance market positioning, the company underscores its ongoing dedication to improving lives through innovative radiation therapy solutions.

About Accuray

Headquartered in Madison, Wisconsin, Accuray specializes in developing advanced radiation therapy technologies. Their focus extends to creating market-changing therapies that allow for the treatment of complex cases while simplifying the processes involved in treating more common cases. By continuing to innovate, they aim to enhance patient care by ensuring timely treatment and a swift return to daily life for those afflicted by serious health conditions.

Conclusion

The upcoming reverse stock split serves as a critical turning point for Accuray. Investors and stakeholders alike will be closely monitoring its outcomes as it strives to return to a strong financial position while meeting the framework required for continued listing on Nasdaq. With a commitment to progress and innovation in the realm of healthcare, Accuray is poised to navigate these changes effectively and remain a key player in the medical technology landscape.